Hypercalcemia is a common metabolic abnormality encountered across ambulatory and inpatient clinical settings. Total serum calcium reflects a balance between intestinal absorption, skeletal resorption, and renal reabsorption, tightly regulated by Parathyroid Hormone (PTH), 1,25-dihydroxyvitamin D (Calcitriol), and Calcitonin.

When serum calcium concentrations rise above normal physiologic limits (typically defined as total corrected calcium > 10.5 mg/dL or ionized calcium > 1.30 mmol/L), the clinical manifestations can range from asymptomatic laboratory findings to life-threatening acute hypercalcemic crisis ("bones, stones, abdominal groans, and psychic moans").

Etiologically, more than 90% of all hypercalcemia cases are accounted for by two distinct clinical entities: Primary Hyperparathyroidism (PHPT) and Hypercalcemia of Malignancy (HCM).

Differentiating between these two pathways is the central objective of the initial diagnostic evaluation. Measuring intact parathyroid hormone (iPTH) serves as the primary branching point that separates autonomous parathyroid adenomas from aggressive paraneoplastic syndromes.

1. Calcium Homeostasis and the Mathematical Correction for Albumin

In human serum, approximately 40% to 45% of total calcium is bound to circulating plasma proteins (principally albumin), 10% to 15% is complexed with anions (phosphate, citrate, bicarbonate), and 45% to 50% exists in the biologically active, unbound ionized form.

Because routine automated laboratory panels measure total serum calcium, fluctuations in serum albumin concentration distort total calcium interpretation:

• Hypoalbuminemia Effect: A drop in serum albumin (frequent in chronic liver disease, nephrotic syndrome, malnutrition, or critical illness) lowers measured total calcium even when biologically active ionized calcium remains entirely normal (pseudohypocalcemia).
• Albumin-Correction Formula (Payne's Formula): \text{Corrected Calcium (mg/dL)} = \text{Total Calcium (mg/dL)} + 0.8 \times \left(4.0 - \text{Serum Albumin (g/dL)}\right)
• Direct Ionized Calcium Measurement: Whenever total corrected calcium is borderline, or when significant acid-base disturbances alter calcium-protein binding (alkalemia increases albumin binding, reducing ionized calcium; acidemia decreases binding, elevating ionized calcium), ordering direct whole-blood ionized calcium via arterial or venous blood gas is the clinical standard.

2. The Primary Diagnostic Pivot: Intact Parathyroid Hormone (iPTH)

Once true hypercalcemia is confirmed, obtaining an Intact Parathyroid Hormone (iPTH) level divides the clinical workup into two pathways:

• Category 1: PTH-Dependent Hypercalcemia (Elevated or Inappropriately Normal iPTH):

• In the presence of elevated circulating calcium, normal physiological negative feedback on the calcium-sensing receptor (CaSR) in the parathyroid glands should suppress PTH secretion to near-zero levels (< 10 to 15 pg/mL).
• Finding an elevated or even mid-to-high "normal" iPTH level in the setting of hypercalcemia indicates autonomous, unregulated parathyroid hormone secretion—primarily Primary Hyperparathyroidism (PHPT), Tertiary Hyperparathyroidism, or Familial Hypocalciuric Hypercalcemia (FHH).

• Category 2: PTH-Independent Hypercalcemia (Suppressed iPTH, typically < 10–15 pg/mL):

• When iPTH is appropriately suppressed by hypercalcemia, the calcium surge is driven by extrinsic factors acting directly on bone or the gastrointestinal tract—principally Solid and Hematologic Malignancies, Granulomatous Disorders, Vitamin D Intoxication, Immobilization, or Medications (thiazide diuretics, lithium, teriparatide, excessive calcium carbonate).

3. PTH-Dependent Workup: PHPT vs. Familial Hypocalciuric Hypercalcemia (FHH)

When hypercalcemia presents with inappropriately non-suppressed iPTH, the immediate diagnostic task is distinguishing common Primary Hyperparathyroidism from benign Familial Hypocalciuric Hypercalcemia to prevent unnecessary neck surgery.

• Primary Hyperparathyroidism (PHPT):

• Etiology: Solitary benign parathyroid adenoma (80% to 85%), multiglandular parathyroid hyperplasia (10% to 15%), or rare parathyroid carcinoma (< 1%).
• Biochemical Signature: High/high-normal calcium, high/inappropriately normal iPTH, low or low-normal serum phosphate (due to PTH-induced renal phosphate wasting), and high-normal or elevated 24-hour urinary calcium excretion (> 200–300 mg/24h).

• Familial Hypocalciuric Hypercalcemia (FHH):

• Etiology: Autosomal dominant loss-of-function mutation in the Calcium-Sensing Receptor (CASR) gene, shifting the parathyroid and renal set-point for calcium sensing upward. The parathyroids perceive normal calcium as low, and the renal tubules avidly reabsorb calcium.
• Clinical Significance: Benign, asymptomatic condition requiring zero medical or surgical treatment; parathyroidectomy fails to correct the hypercalcemia.

• The 24-Hour Calcium-to-Creatinine Clearance Ratio (CCCR): \text{CCCR} = \frac{\text{24-Hour Urine Calcium} \times \text{Serum Creatinine}}{\text{Serum Calcium} \times \text{24-Hour Urine Creatinine}}

• A \text{CCCR} < 0.01 strongly indicates Familial Hypocalciuric Hypercalcemia (FHH).
• A \text{CCCR} > 0.02 strongly indicates Primary Hyperparathyroidism (PHPT).
• Values between 0.01 and 0.02 represent an equivocal grey zone requiring genetic CASR sequencing and familial screening.

4. PTH-Independent Workup: Malignancy Pathways and Secondary Mediators

When iPTH is suppressed (< 15 pg/mL), clinicians must systematically evaluate for occult or known malignancies and granulomatous cascades by ordering secondary biomarkers:

• 1. Humoral Hypercalcemia of Malignancy (PTHrP Pathway - 80% of HCM):

• Mechanism: Solid tumors secrete Parathyroid Hormone-Related Protein (PTHrP), which shares amino-terminal homology with native PTH. PTHrP binds to the shared \text{PTH/PTHrP receptor (Type 1 PTHR)} in bone and kidney, stimulating osteoclast-mediated bone resorption and renal tubular calcium reabsorption while suppressing native iPTH.
• Associated Tumors: Squamous cell carcinomas (lung, head and neck, esophagus), renal cell carcinoma, ovarian cancer, and breast carcinoma.
• Laboratory Markers: Suppressed iPTH, elevated serum PTHrP, suppressed 1,25-dihydroxyvitamin D, and low serum phosphate.

• 2. Local Osteolytic Hypercalcemia (20% of HCM):

• Mechanism: Direct skeletal metastasis and marrow infiltration by tumor cells producing localized osteolytic cytokines (IL-1, IL-6, TNF-alpha, RANK-Ligand), which activate osteoclasts and cause extensive physical bone destruction.
• Associated Tumors: Multiple Myeloma, metastatic Breast Cancer, and non-small cell lung carcinoma.
• Laboratory Markers: Suppressed iPTH, normal/low PTHrP, normal calcitriol, markedly elevated alkaline phosphatase (or normal in pure lytic myeloma), and extensive lytic bone lesions on skeletal survey or PET-CT.

• 3. 1,25-Dihydroxyvitamin D (Calcitriol) Mediated Hypercalcemia:

• Mechanism: Extra-renal production of 1-alpha-hydroxylase enzyme by disease-associated macrophages or lymphoma cells, converting 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D independent of PTH feedback. This causes hyper-absorption of dietary calcium in the gut.
• Associated Conditions: Hodgkin and Non-Hodgkin Lymphomas, alongside chronic granulomatous diseases (Sarcoidosis, Tuberculosis, Berylliosis, Histoplasmosis, Coccidioidomycosis).
• Laboratory Markers: Suppressed iPTH, suppressed PTHrP, normal 25-hydroxyvitamin D, and elevated 1,25-dihydroxyvitamin D (Calcitriol).

• 4. Pure Vitamin D Intoxication:

• Mechanism: Ingestion of massive exogenous doses of Vitamin D3 or D2 (> 50,000–100,000 IU/day for months).
• Laboratory Markers: Suppressed iPTH, suppressed PTHrP, massive elevation of 25-Hydroxyvitamin D [25(OH)D > 150 ng/mL], and normal or mildly elevated calcitriol.

5. Structural Comparison: Laboratory Profiles Across Major Hypercalcemic States

• Primary Hyperparathyroidism (PHPT):

• Total Corrected Calcium: Elevated.
• Intact PTH (iPTH): Elevated or Inappropriately Normal.
• Serum Phosphate: Low or Low-Normal.
• Serum PTHrP: Undetectable / Normal.
• 25-Hydroxyvitamin D: Normal or Deficient.
• 1,25-Dihydroxyvitamin D: High or High-Normal.
• 24-Hour Urine Calcium / CCCR: Elevated / CCCR > 0.02.

• Familial Hypocalciuric Hypercalcemia (FHH):

• Total Corrected Calcium: Mildly Elevated.
• Intact PTH (iPTH): Inappropriately Normal or Mildly High.
• Serum Phosphate: Normal or Low-Normal.
• Serum PTHrP: Undetectable / Normal.
• 25-Hydroxyvitamin D: Normal.
• 1,25-Dihydroxyvitamin D: Normal.
• 24-Hour Urine Calcium / CCCR: Very Low (< 100 mg/24h) / CCCR < 0.01.

• Humoral Hypercalcemia of Malignancy (HHM):

• Total Corrected Calcium: Markedly Elevated (> 12–14 mg/dL).
• Intact PTH (iPTH): Suppressed (< 10–15 pg/mL).
• Serum Phosphate: Low (PTHrP drives phosphate wasting).
• Serum PTHrP: Markedly Elevated.
• 25-Hydroxyvitamin D: Normal or Low.
• 1,25-Dihydroxyvitamin D: Low or Suppressed.
• 24-Hour Urine Calcium / CCCR: High (Severe Hypercalciuria).

• Osteolytic Bone Metastases / Multiple Myeloma:

• Total Corrected Calcium: Moderately to Markedly Elevated.
• Intact PTH (iPTH): Suppressed (< 10–15 pg/mL).
• Serum Phosphate: Normal or High (released from lysed bone matrix).
• Serum PTHrP: Undetectable / Normal.
• 25-Hydroxyvitamin D: Normal.
• 1,25-Dihydroxyvitamin D: Low or Normal.
• 24-Hour Urine Calcium / CCCR: Markedly Elevated.

• Granulomatous Disorders / Lymphoma:

• Total Corrected Calcium: Moderately Elevated.
• Intact PTH (iPTH): Suppressed (< 10–15 pg/mL).
• Serum Phosphate: Normal or High (calcitriol increases gut phosphate absorption).
• Serum PTHrP: Normal.
• 25-Hydroxyvitamin D: Normal.
• 1,25-Dihydroxyvitamin D: Markedly Elevated.
• 24-Hour Urine Calcium / CCCR: High.

6. Strategic Clinical Roadmap for Evaluating Hypercalcemia

When evaluating a patient presenting with an elevated serum calcium level, clinicians should execute a structured diagnostic sequence:

• Step 1: Verify True Hypercalcemia: Calculate albumin-corrected calcium. If borderline or in critical illness, obtain direct ionized calcium via blood gas; repeat the sample to confirm persistence.
• Step 2: Obtain Simultaneous Intact PTH (iPTH): Draw serum iPTH on a confirmed hypercalcemic blood sample to establish whether the mechanism is PTH-dependent or PTH-independent.
• Step 3: Branch A — If iPTH is Elevated or Inappropriately Normal:

• Measure 24-hour urinary calcium and creatinine to calculate the Calcium-to-Creatinine Clearance Ratio (CCCR).
• If \text{CCCR} < 0.01: Diagnose Familial Hypocalciuric Hypercalcemia (FHH); cancel surgery and test family members.
• If \text{CCCR} > 0.02: Diagnose Primary Hyperparathyroidism (PHPT). Proceed to pre-operative anatomical localization with Neck Ultrasound, 4D-CT of the Parathyroids, or 99mTc-Sestamibi SPECT/CT for minimally invasive parathyroidectomy planning.

• Step 4: Branch B — If iPTH is Suppressed (< 15 pg/mL):

• Order a secondary laboratory panel: Serum PTHrP, 25-Hydroxyvitamin D, 1,25-Dihydroxyvitamin D, and Serum/Urine Protein Electrophoresis with Immunofixation (SPEP/UPEP and Free Light Chains).
• If PTHrP is elevated: Perform urgent cross-sectional imaging (CT chest/abdomen/pelvis) to locate an underlying solid-organ squamous cell or renal malignancy.
• If 1,25-dihydroxyvitamin D is elevated: Perform chest CT to evaluate for pulmonary sarcoidosis or tuberculosis, and order peripheral lymph node ultrasound/biopsy for lymphoma staging.
• If SPEP/UPEP reveals a monoclonal spike: Perform bone marrow biopsy and low-dose whole-body skeletal CT for Multiple Myeloma.

• Step 5: Immediate Acute Hypercalcemia Crisis Management: If corrected calcium exceeds 14.0 mg/dL or if the patient exhibits altered mental status, cardiac arrhythmias, or acute renal failure:

• Initiate immediate aggressive volume expansion with Intravenous Isotonic Normal Saline (0.9% NaCl at 200–300 mL/hr) to restore intravascular volume and enhance renal calcium excretion.
• Administer Intravenous Bisphosphonates (Zoledronic Acid 4 mg IV over 15 minutes) or Subcutaneous Denosumab (120 mg) to halt osteoclastic bone resorption.
• Administer Subcutaneous Calcitonin (4 to 8 IU/kg every 12 hours) for rapid, transient calcium lowering over the initial 24 to 48 hours while awaiting bisphosphonate onset.
• Add Systemic Corticosteroids (Prednisone 20–40 mg/day) if hypercalcemia is driven by lymphoma, granulomatous sarcoidosis, or Vitamin D toxicity.

10 Frequently Asked Questions (FAQs)

Q1. Why is an "inappropriately normal" PTH level diagnostic of primary hyperparathyroidism?

In healthy physiology, high circulating calcium suppresses PTH production down to near-zero levels via the calcium-sensing receptor. Finding a PTH level in the "normal reference range" (e.g., 35 pg/mL) during hypercalcemia demonstrates that the parathyroid glands are failing to respond to negative feedback, confirming autonomous hypersecretion.

Q2. What is the difference between Primary, Secondary, and Tertiary Hyperparathyroidism?

• Primary: Autonomous hypersecretion of PTH by a parathyroid adenoma or hyperplasia, causing hypercalcemia.
• Secondary: Physiological compensatory increase in PTH driven by chronic hypocalcemia or vitamin D deficiency, commonly seen in chronic kidney disease (calcium is low or low-normal).
• Tertiary: Long-standing secondary hyperparathyroidism in chronic kidney disease that becomes autonomous, where hypertrophied parathyroid glands continue secreting high PTH even after renal transplantation, resulting in hypercalcemia.

Q3. Why are thiazide diuretics and lithium important to identify during a hypercalcemia workup?

Thiazide diuretics increase distal renal tubular reabsorption of calcium, unmasking underlying primary hyperparathyroidism or causing mild transient hypercalcemia. Lithium shifts the calcium-sensing receptor threshold to the right, requiring higher calcium levels to suppress PTH and mimicking the biochemical profile of primary hyperparathyroidism.

Q4. How does Humoral Hypercalcemia of Malignancy (HHM) differ from bone metastasis?

HHM is driven by systemic circulation of tumor-derived PTHrP from a distant solid tumor without direct bone involvement. Osteolytic hypercalcemia is caused by physical tumor metastases within the bone marrow producing localized osteoclast-activating cytokines that mechanically degrade the bone matrix.

Q5. Why does standard PTH testing fail to detect Parathyroid Hormone-Related Protein (PTHrP)?

Standard intact PTH immunoassays use antibodies specific to unique amino acid sequences within the middle and carboxy-terminal regions of the native human PTH molecule. Because PTHrP only shares structural homology in its first 13 amino-terminal amino acids, native PTH assays do not cross-react with PTHrP, necessitating a dedicated PTHrP assay.

Q6. What role do corticosteroids play in treating hypercalcemia?

Corticosteroids (such as prednisone 20 to 40 mg daily) inhibit the 1-alpha-hydroxylase enzyme in macrophages and lymphoma cells, downregulating the overproduction of active 1,25-dihydroxyvitamin D. They also decrease intestinal calcium absorption, making them the treatment of choice for hypercalcemia caused by sarcoidosis, lymphoma, or Vitamin D toxicity.

Q7. Why is loop diuretic (furosemide) therapy no longer routinely used in initial hypercalcemia stabilization?

Historically, high-dose furosemide was given to force renal calcium excretion. However, hypercalcemic patients are already severely volume-depleted due to calcium-induced nephrogenic diabetes insipidus. Giving loop diuretics before complete intravascular volume rehydration worsens dehydration and reduces the glomerular filtration rate, exacerbating hypercalcemia. Furosemide is now reserved solely for managing volume overload during saline resuscitation.

Q8. What is the classic electrocardiogram (ECG) abnormality seen in severe hypercalcemia?

The classic ECG finding in acute hypercalcemia is a shortened QT interval (specifically a shortened ST segment), caused by accelerated cardiac ventricular repolarization. Severe cases can also exhibit widened T-waves, bradycardia, heart blocks, or Osborn waves (J-waves).

Q9. When is parathyroidectomy indicated for asymptomatic Primary Hyperparathyroidism?

According to international consensus guidelines, parathyroid surgery is indicated in asymptomatic PHPT if any of the following criteria are met: serum calcium > 1.0 mg/dL above the upper normal limit; T-score <= -2.5 at any site (lumbar spine, hip, or distal radius) or vertebral fracture on imaging; eGFR < 60 mL/min; 24-hour urine calcium > 250 mg (women) or > 300 mg (men) with nephrolithiasis/nephrocalcinosis; or patient age < 50 years.

Q10. How quickly do intravenous bisphosphonates lower serum calcium in malignancy-associated hypercalcemia?

Intravenous bisphosphonates (such as Zoledronic Acid 4 mg IV) begin inhibiting osteoclastic bone resorption within 24 to 48 hours, reaching their peak nadir of serum calcium reduction between Day 4 and Day 7 post-infusion, with therapeutic effects lasting 2 to 4 weeks.